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 Hyperparathyroidism-jaw tumor (HPT-JT) syndrome is a rare but damaging 
disease that is characterized by a plethora of tumors, including parathyroid tumors, renal 
cysts or tumors, uterine tumors, and ossifying jaw fibromas. The cause of this syndrome 
can be traced back to a tumor suppressor gene called Hrpt2, now renamed Cdc73, which 
encodes for the protein product parafibromin. Parafibromin is a part of the Paf1 complex, 
which interacts with RNA polymerase II, playing a role in transcriptional initiation and 
elongation. The loss of proper expression of Cdc73 and its protein product parafibromin 
are implicated in the development of the various types of tumors that are typical of HPT-
JT, although the exact mechanisms of tumorigenesis are unclear. In particular, not much 
is understood about how the loss of Cdc73/parafibromin contributes to the development 
of ossifying fibromas (OF) of the jaw. OF is a benign bone neoplasm that can affect both 
the mandible and maxilla, and consists of fibrous tissue in the place of bone. The goal of 
this research was to deepen the understanding of the role Cdc73/parafibromin plays in the 
development of OF through creating a mouse model of OF. Using Wnt1 as a Cre driver 
with Cdc73-floxed mice, Cdc73 loss was targeted to the cranial neural crest of the mouse. 
However, homozygous knockouts of Cdc73 in the cranial neural crest proved to be 
embryonic lethal by day 13. Upon investigation of these embryos, the presence of 
apoptosis was discovered in both the mandible and the midbrain, the latter of which is the 
likely cause of embryonic lethality. This finding provides further evidence that the 
normal expression of Cdc73/parafibromin plays an essential role in embryonic 
development. Heterozygous null mice were viable and healthy, and were followed out to 
15 months. Histological analysis of their jaws revealed no development of OF or any 
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other abnormalities, indicating that the development of these tumors requires biallelic 
inactivation of Cdc73 and the amount of time it takes to acquire a second somatic 
mutation to cause loss of heterozygosity is substantial. Parafibromin was detected 
throughout the jaw tissue, the presence of which is also consistent with a tumor 
suppressor model in which the remaining copy of Cdc73 can produce enough 
parafibromin in order to maintain normal function.  
 
Introduction 
 A familial disease inherited in an autosomal dominant manner, 
hyperparathyroidism-jaw tumor (HPT-JT) syndrome places patients at risk for multiple 
types of neoplasia. As indicated by the name, patients often present with 
hyperparathyroidism as a result of the parathyroid tumors developed in this syndrome. 
These parathyroid tumors are usually parathyroid adenomas; however, what makes this 
condition particularly aggressive compared to other hereditary causes of 
hyperparathyroidism is that >15% of patients afflicted with HPT-JT develop parathyroid 
carcinomas1, a malignant tumor that can lead to serious clinical manifestations, and is 
normally extremely rare in the general population. Compared to other types of familial 
hyperparathyroidism, patients with HPT-JT oftentimes have more severe hypercalcemia1 
and up to 50% of patients will also experience kidney or bone disease2. Other presenting 
symptoms of parathyroid carcinomas include fatigue, weakness, weight loss, anorexia, 
polyuria, and polydipsia2. The ideal treatment for parathyroid carcinomas is an en bloc 
resection of the tumor, which if performed successfully, has a 90% long-term survival 
rate2. However, incomplete resection increases recurrence rate, usually at the original 
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site, and subsequent mortality from the long-term consequences of hypercalcemia. In a 
case study, out of 10 recurrences that occurred in less than 2 years since initial removal of 
the carcinoma, 9 cases resulted in patient death3. Even for recurrences occurring over 2 
years later, 3 out of 8 patients did not survive3, although this is a better survival rate. 
Overall, the mortality rate for reoccurrences in this case study was 66%. The majority of 
recurrences also resulted in metastases. Therefore, when not treated successfully or 
becoming invasive, the prognosis for parathyroid carcinoma can become quite poor.  
Along with parathyroid adenomas and carcinomas, >15% of patients with HPT-JT 
can also develop renal tumors, including Wilms’ tumors, hamartomas, and carcinomas4. 
About 75% of female patients who develop HPT-JT also find themselves with benign or 
malignant tumors of the uterus5. Finally, about 30% of HPT-JT patients develop ossifying 
fibromas of the jaw, benign neoplasms that can manifest in the mandible or maxilla.  
 Patients with HPT-JT often present first with an ossifying fibroma of the jaw6. In 
fact, OFs can be found in HPT-JT patients that show no evidence of the characteristic 
parathyroid tumors or hyperparathyroidism7. Ossifying fibromas (OF) are tumors in the 
bone that consist of a highly cellular fibrous tissue, either calcified tissue that resembles 
bone, cementum, or a varying amount of both. The mandible is the most commonly 
affected site, and although an OF can present at any position throughout the mandible, it 
presents most frequently inferior to the premolars and molars8. This concurs with the 
conventional belief that OFs are thought to originate from the periodontal ligament, 
which surrounds the tooth-bearing areas of the jaws. The peak age for the development of 
OF appears to be in the middle-aged range of adulthood, between 20 to 40 years of age8,9. 
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OF seems to show a predominance towards females, who are up to five times more likely 
to develop this neoplasm than their male counterparts9.  
 A characteristic of OF that distinguishes it from other types of fibrous lesions or 
dysplasia is a well-defined growth pattern. The slow-growing, progressive expansion of 
the bone is marked by smooth, relatively well-demarcated radiographic borders8,9. In 
most cases, the growth tends to be round with concentric outgrowth that is approximately 
regular in all directions8. OFs can also appear to be irregular in shape, especially if they 
are recurrent or if they grow very rapidly in a short period of time. In these cases of a 
recurrent OF or of aggressive local growth, the tumors can encompass the entire jaw 
bone, appearing as one large, irregularly shaped mass8.  
OFs are benign neoplasms; however, they can grow large enough to cause 
damage to the surrounding tooth-bearing areas of the jaw as well as general cosmetic 
concerns such as visible outgrowths of the jaw and facial asymmetry for patients who are 
afflicted. The expansion of the tumor can lead to tooth displacement and even resorption 
of tooth roots8. Often times, the lamina dura is also missing from the displaced teeth. Left 
untreated, an OF will continue to expand and can become severely disfiguring to the 
face6. If severe enough, the displacement caused by a particularly large OF can hinder an 
afflicted patient’s ability to take in food. Treatment of OF requires radical surgery 
involving complete excision of the tumor along its well-demarcated lines8. Larger tumors 
may require resection with an additional small margin9. Though capable, the vast 
majority of OFs do not recur after being surgically removed as long as the resection is 
complete.  
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 The development of HPT-JT has been genetically linked to a tumor-suppressor 
gene called Hrpt2, now renamed Cdc73. This gene was identified in chromosome 1q24-
q321, and encodes a protein product called parafibromin. Germline mutations in Cdc73 
that are expected to produce loss of function in parafibromin through truncation or 
premature stops have been reported, lending evidence that this gene plays a significant 
role in the pathogenesis of HPT-JT. Additional inactivating mutations in conjunction with 
already present germline mutations have also been reported in the parathyroid tumors of 
certain kindreds afflicted with HPT-JT1,10. This advent of loss of heterozygosity provides 
evidence that the development of HPT-JT requires biallelic inactivation of Cdc73 in order 
to manifest, a clear marker of a tumor-suppressor mechanism of pathogenesis. Such 
inactivating mutations were not detected in adjacent non-tumor tissue or in patients who 
are not afflicted with HPT-JT1, suggesting that the mutations in Cdc73 were directly 
related to the pathogenesis of HPT-JT.  
 The protein product of Cdc73, parafibromin, is composed of 531 amino acids and 
is predominately found in the nucleus11. It has been identified as a part of the Paf1 
complex, and involved in processes such as transcription elongation and 
posttranscriptional events, such as 3’ end processing11,12. Parafibromin can also associate 
with the large subunit of RNA polymerase II in the process of transcription. This 
interaction is contingent on a C-terminal domain on the protein, which is commonly 
affected by 80% of clinically relevant mutations in Cdc73. These mutations result in 
premature truncations that can delete more than half of this C-terminal domain on 
parafibromin, hindering its normal function to regulate transcription. Down regulation of 
parafibromin has also been shown to increase entry into the S phase of cell division12, 
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spawning a theory that parafibromin has the ability to inhibit the cell cycle, although the 
mechanism by which it does this is unknown. This however, concurs with the idea that 
Cdc73 is a tumor suppressor gene—the loss of normal function of parafibromin can leave 
cell division unchecked, leading to the development of the typical cancerous growths 
seen in HPT-JT.  
 Given Cdc73/parafibromin’s significant role in the development of HPT-JT, 
mouse models in which normal Cdc73/parafibromin expression have been knocked out 
have been created in an effort to study the mechanisms of tumorigenesis in HPT-JT, 
albeit to varying degrees of success. In conventional knockouts of Cdc73, wild-type and 
heterozygote adult mice were viable and fertile but homozygote mice were not, showing 
embryonic lethality as early as embryonic day 6.513. Heterozygote adult mice of 
conventional Cdc73 knockouts were able to develop parathyroid tumors including 
parathyroid adenomas, parathyroid carcinomas, and other atypical parathyroid adenomas, 
representative of the tumors found in HPT-JT14. Female heterozygotes developed uterine 
neoplasms as well, another hallmark of HPT-JT14. Their wild-type counterparts did not 
develop tumors of any kind. Both these parathyroid and uterine tumors showed a 
reduction, or even a complete lack of normal nuclear expression of parafibromin14, again 
concurring with the tumor suppressor role of Cdc73. OFs were not found in the 
heterozygote conventional knockouts; however, they did have an increased mandibular 
cell proliferation rate14, which may represent a possible early phase with potential for 
tumorigenesis in the future.  
In addition to conventional models, a conditional knockout of Cdc73 specific to 
the parathyroid has also been created by mating Cdc73-floxed mice with transgenic PTH-
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Cre mice, localizing the loss of Cdc73 to the parathyroid. Unlike the conventional 
knockout model, both heterozygous and homozygous mice with knockouts of Cdc73 
restricted within the parathyroid were viable. Within these mice, which either had one or 
both alleles of Cdc73 deleted in the parathyroid, >40% displayed parathyroid tumor 
development14. Similarly, their wild-type counterparts did not develop any tumors. The 
previously described conventional knockout of Cdc73, and this parathyroid-specific 
knockout provide a model with which to investigate the molecular basis of tumorigenesis 
in HPT-JT.  
Despite the successful creation of mouse models for the parathyroid tumors and 
uterine tumors seen in HPT-JT, there has been a lack of mouse models for OFs in HPT-
JT and little is known about how the loss of Cdc73 and its protein product parafibromin 
contributes to the development of these jaw tumors, which have not been studied so 
extensively as the other characteristic tumors of the syndrome. A few somatic and 
germline mutations have been discovered in sporadic OFs15; however, whether these 
cases are related to HPT-JT cannot be determined, and it is not necessarily revealing of 
how mutations in Cdc73 contribute directly to the development of the tumor. Therefore, 
the aim of this project was to model OF in mice in the hopes of discovering some ideas 




 In order to produce a transgenic mouse model for OF, Cdc73-floxed mice were 
crossed with Wnt1-Cre mice, generating offspring that were Cre-positive and 
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heterozygous for the LoxP sites 
surrounding the target gene. These 
mice were then crossed again with 
Cdc73-floxed mice to produce 
offspring that was both Cre-positive 
and homozygous for Cdc73 LoxP 
sites, effectively knocking out the 
gene. The use of Wnt1 as a Cre driver 
localizes Cdc73 deletion to the 
craniofacial bones. Wnt1 expression 
occurs in migrating neural crest cells, 
which arise in the midbrain and 
hindbrain, and proliferate into the 
frontonasal, maxillary, and 
mandibular prominences16. Therefore, 
homozygous Cdc73 deletion is 
restricted to the jaw of the mouse.  
 
Timed Pregnancies  
 After it was discovered that homozygous knockouts of Cdc73 in the jaw resulted 
in embryonic lethality, timed pregnancies were performed instead in order to assess the 
morphology of the homozygous knockout embryos before they were resorbed in utero, as 
well as to perform chemical staining to assay for apoptosis throughout the embryonic 
Figure 2: Breeding Scheme. Green bars indicate a normal 
allele of Cdc73. Red bars indicate an allele of Cdc73 that is 
surrounded by LoxP sites. The Wnt1-Cre mediated 
homozygous knockout of Cdc73 is created using two crosses 
with Cdc73-floxed mice. 
Figure 1: Cdc73-Floxed Construct. The LoxP sites flanking 
the Cdc73 gene represent the sites where the gene will be cut 
when the Wnt1-Cre driver proliferates. 
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tissue. Euthanization of the mother was generally performed at approximately embryonic 
day 11-13. Embryos were harvested, genotyped, and then embedded into paraffin blocks 
to be sectioned for further chemical and histological analysis.  
 
Immunohistochemistry  
 The location and presence of apoptotic cells throughout the embryonic tissue of 
the homozygous cranial neural crest Cdc73 knockouts was assessed by 
immunohistochemical (IHC) staining techniques. 
The primary antibody used was Cleaved 
Caspase-3 (Asp175) (5A1E) Rabbit 
mAB, an antibody specific to cleaved 
caspase-3, a protein involved in cell 
death. Caspases play an integral role in 
cellular apoptosis, but normally exist as 
inactive enzymes within the cell. During 
the signaling process for apoptosis, 
initiator caspases cleave effector 
caspases such as caspase-3, thereby 
activating it so it can carry out its 
function of proteolytically degrading 
intracellular proteins and organelles, 
ultimately leading to the death of the cell. Therefore, the presence of cleaved caspase-3 
indicates that apoptosis has occurred in the cell. Slides were incubated with the antibody 
Figure 3: IHC Diagram. Immunohistochemical staining 
techniques utilize a primary antibody that binds to the protein of 
interest. The secondary antibody binds to the primary antibody, 
and has an enzyme attached that can generate a colored product 
when substrate is introduced, identifying the presence of the 
desired protein. 
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overnight, before being treated with a secondary antibody, ImmPRESS Anti-Rabbit IgG, 
that contained an enzyme that could produce a colored product. DAB Chromogen was 
used as a substrate, which was converted by the enzyme into the brown colored staining 
indicative of a cell positive for cleaved caspase-3. After the IHC staining was complete, 
the slide was counterstained with hematoxylin, observed under a light microscope, and 
scored for instances of positive staining using the table shown below.  
 1 2 3 4 5 
% positive 
cells 
<10% 10-25% 25-50% 50-75% >75% 
 
 0 1 2 3 
Positive 
structures 
Neither Nuclei only Cytoplasm only Both 
 





Weak  Moderate Intense 
Figure 4: IHC Scoring Chart. Slides were scored for the percentage of positive cells, the location of staining within 
the cell, and the intensity of the staining based on the scale shown above.  
 
Jaw Prep for Heterozygous Null Mice 
 Heterozygous null mice are positive for the Cre driver and heterozygous for LoxP 
sites flanking the gene Cdc73, meaning they only have one copy of Cdc73 in their 
craniofacial bones. These heterozygous null mice were followed out to 15 months, and 
were viable and healthy. Their jaws were harvested, embedded into paraffin blocks, and 
sectioned for histological analysis and immunohistochemical staining. For histological 
analysis, a hematoxylin and eosin (H&E) stain was performed. IHC staining for 
heterozygous null mice jaws was also done. It utilized the Parafibromin (2H1) antibody 
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in order to assess for the presence of the protein within the tissue. The antibody was 
incubated for an hour only in order to reduce the amount of background staining as it was 
a mouse-on-mouse antibody. After the IHC was complete, slides were also 
counterstained with hematoxylin. Slides were scored using the same scale used for the 
IHC staining of the homozygous knockout embryos.  
 
Results 
The number of observed births from initial crosses is summarized in Figure 5. As 
can be seen from the table, there were live births 
obtained of all the listed genotypes except for the 
homozygous cranial neural crest knockouts, 
identified as Cre+ F/F in the table. It is 
statistically unlikely for there to be absolutely no 
live births of the homozygous cranial neural crest 
knockouts as the correct ratio over time for these 
listed genotypes (from top to bottom as shown in 
the table) should be approximately 2:1:2:1. 
However, the actual observed ratio was 1:1:1:0, indicating that the homozygous cranial 
neural crest knockouts are embryonic lethal, therefore resulting in the lack of live births 
and the skewing of the actual genotype ratio. 
The homozygous cranial neural crest knockouts of Cdc73 that were harvested 
from embryonic day 13 and beyond, were oftentimes smaller with gross morphological 
abnormalities than embryos of the wild-type and heterozygous genotypes. It is likely that 
Genotype Number of Live 
Births 
Cre- F/+ 24 
Cre- F/F 27 
Cre+ F/+ 21 
Cre+ F/F 0 
Figure 5: Table of Live Births Observed. Cre+ 
indicates the presence of the Wnt1-Cre driver while 
Cre- indicates the lack of it. F/F indicates a mouse 
that is homozygous for LoxP sites on Cdc73. F/+ 
indicates a mouse that is heterozygous for LoxP 
sites on Cdc73. No live births of homozygous 
cranial neural crest knockouts (Cre+ F/F) were 
observed.  
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these embryos have already begun to 
become resorbed in utero after their 
death in the womb. Therefore, 
embryonic lethality in this line of 
knockout mice must’ve occurred at 
approximately embryonic day 13.  
 
IHC staining on the harvested homozygous knockout embryos with an antibody 
for cleaved caspase-3 revealed positive staining in various locations throughout the 
embryonic tissue. A certain level of apoptosis is typically associated with an embryo in 
development and can be considered normal. Therefore, not all cases of staining were 
considered to be significant. Instead, the focus was more on locating apoptosis in places 
of the tissue where the Cre driver, Wnt1, is known to be expressed, as these tissues would 
be the site of Cdc73/parafibromin loss following the knockout. With these considerations, 
positive staining revealed the presence of apoptosis in the mandible and the midbrain, the 
two primary locations where Wnt1 proliferates during development and where normal 
Cdc73/parafibromin expression would’ve been lost.  
Heterozygous null mice were healthy and viable, but it was still pertinent to assess 
whether or not they had shown any development of OF over their lifetimes. Histological 
analysis after an H&E stain of the jaw bones from heterozygous null mice, followed out 
to 15 months, were completely normal and did not show any signs of OF or any 
morphological abnormalities.  
 
Figure 6: Gross morphology of harvested embryos. a) A 
healthy, viable embryo shows no gross morphological 
abnormalities. b) A homozygous cranial neural crest knockout of 
Cdc73 is smaller than its healthy counterpart and is 
morphologically stunted. c) Homozygous knockout embryos 
harvested after embryonic day 13 have already begun to be 




Figure 7: IHC Staining Results for Cleaved Caspase-3. Positive (brown) staining was found in the midbrain area of 
a homozygous Cdc73 cranial neural crest knockout at embryonic day 11-11.5, indicating the presence of apoptosis. 
Scores: % positive cells – 1, positive structures – 3, intensity of staining –  +++.  
 
 
Figure 8: H&E Stain of Jaw Bone. Jaw from a heterozygous null mice, followed out to 15 months, shows that the 
tissue is healthy and does not exhibit any development of OF or morphological abnormalities.  
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Finally, IHC staining with an antibody for parafibromin was also performed on 
these jaw sections from heterozygous null mice. The bone tissue was fragile and did not 
handle staining procedures well, resulting in lifting, folding, and sometimes even 
completely washing off of bone tissue from the slide. Positive staining did occur in the 
bone; however it was more difficult to observe and did not produce as clear results as 
staining elsewhere. The majority of the positive staining was observed fairly ubiquitously 
throughout the surrounding epithelial and muscular tissue of the jaw, most notably in the 
periodontal ligament of the tooth-bearing areas. 
 
 
Figure 9: IHC Staining Results for Parafibromin. Positive (brown) staining for parafibromin was found in the 
periodontal ligament of the tooth-bearing areas of the jaws in heterozygous null mice. Scores: % positive cells – 4, 
positive structures – 3, intensity of staining – ++.  
 
Discussion 
 The original aim of this project was to develop a mouse model for the OFs seen in 
HPT-JT as a method of studying the mechanisms of development of this specific tumor.  
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The homozygous cranial neural crest knockouts of Cdc73 were discovered to be 
embryonic lethal, similar to conventional knockouts of Cdc73, which meant the study of 
tumorigenesis of OFs was not possible using this model. However, analysis of these 
homozygous cranial neural crest knockouts and their heterozygous null counterparts does 
have some important implications.   
 The homozygous cranial neural crest knockouts were lethal by embryonic day 13, 
which is longer than previous conventional knockouts of Cdc73. Conventional knockouts 
of Cdc73 have been embryonic lethal as early as embryonic day 6.5 with lethality likely 
occurring at the hatching stage or implantation stage. In conventional knockouts, wild-
type and heterozygous Cdc73 blastocysts were able to attach to the plate in vitro while 
homozygous blastocysts failed to attach and thus were unable to continue growing13, 
suggesting that their inability to implant was what directly caused the lethality. The 
cranial neural crest knockouts were able to remain viable for longer due to the timing of 
the knockout. This model utilizes Wnt1 as a Cre driver, and the expression of Wnt1 
begins at approximately embryonic day 9.516, effectively knocking out the Cdc73 gene 
starting only from this time point forward. Therefore, this allows the cranial neural crest 
knockouts to bypass the failure of conventional knockouts to implant because normal 
expression of Cdc73 still remains at embryonic day 6.5.  
 Instead, lethality of the homozygous cranial neural crest knockouts was likely 
caused by the presence of apoptosis in the midbrain, and thus a failure to develop 
properly. Wnt1 begins proliferation in the midbrain and the hindbrain, effectively 
knocking out Cdc73 in those areas of the developing embryo as well. The lack of Cdc73 
expression in the midbrain and the subsequent apoptosis that accompanies provides 
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further evidence that normal expression of Cdc73/parafibromin plays a critical role in 
development. In an inducible knockout of Cdc73, injection of tamoxifen at embryonic 
day 10.5 leads to a significant delay in the development of the central nervous system and 
the embryos die rapidly afterwards13. It is likely that a similar phenomenon is occurring 
in this cranial neural crest knockout model as well, especially because expression of Wnt1 
producing the knockout begins at around the same time. The loss of Cdc73 expression 
during this time period is associated with elevated levels of apoptosis in the midbrain that 
become embryonic lethal, implying that proper Cdc73 expression is required for 
development, including in the nervous system.  
 The jaws harvested from 15-month-old heterozygous null cranial neural crest 
knockouts were histologically normal with no sign of OF development. The fact that 
these mice did not develop any jaw tumors indicates that tumorigenesis likely requires 
biallelic inactivation of the Cdc73 gene. This is consistent with the tumor-suppressor role 
of Cdc73, as one copy of the gene is apparently sufficient to sustain normal function 
within the jaw tissue and prevent the development of tumors. Immunohistochemistry 
results for parafibromin showed the presence of the protein within the jaw tissue, most 
significantly in the periodontal ligament, the believed origin of OF. Nuclear staining of 
parafibromin in this region indicates that these mice, despite having lost one allele of 
Cdc73, were still able to produce enough functional protein to maintain normal activity 
and stave off tumor development. Nuclear staining was more difficult to observe in the 
bone tissue as it did not adhere to the slide as well as other surrounding tissue did during 
the staining procedure and so, did not always produce clear results. The relative low 
quantity of cells in the bone matrix itself also made staining difficult to pinpoint. 
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However, staining was still occurring in some cases and the presence of functional 
parafibromin in the bone itself also provides evidence for Cdc73 as a tumor suppressor, 
and that the inactivation of one allele is not enough to cause tumors.  
 For the future, further studies will need to be performed in order to produce a 
successful mouse model that can be used to study the specific mechanisms of 
tumorigenesis for OF. The importance that Cdc73 and parafibromin expression plays in 
embryonic development makes it particularly challenging in creating a successful mouse 
model, especially one targeted for the study of jaw tumors. However, the embryonic 
lethality of the cranial neural crest knockouts of Cdc73 at least provides additional 
evidence that Cdc73 is required for development, and its specific role in embryogenesis 
can become an important area of study. The heterozygous null knockouts reaffirm 
Cdc73’s role as a tumor suppressor, and suggests that the development of tumors can 
occur only when both copies of the gene become nonfunctional. The fact that these 
heterozygous null knockouts did not develop tumors or any other histological 
abnormalities for the entire time that they were followed for 15 months can be seen as a 
reflection of the time it takes to acquire an additional inactivating mutation that causes 
the loss of the last copy of the Cdc73 gene. Loss of heterozygosity is a common 
phenomenon that causes cancer when the last copy of a tumor suppressor gene becomes 
subject to an inactivating mutation. However, loss of heterozygosity is rarer in HPT-JT 
compared to other familial types of hyperparathyroidism, and can suggest that in tumors 
characteristic of HPT-JT, alternative mechanisms aside from loss of heterozygosity may 
be at play7.  
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The study of OF is especially vital as it has not been so extensively studied as the 
other tumors of HPT-JT, such as the parathyroid adenomas. While there have been mouse 
models successfully produced that show the development of parathyroid and uterine 
tumors, there has not been one made for the jaw tumors. The creation of mouse models, 
particularly for OF now, is of utmost importance for elucidating the possibly myriad 
ways in which tumorigenesis can occur and is key to diversifying the knowledge of such 
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